Department of Pharmacy, Federal University of Sergipe , São Cristóvão, Brazil.
Expert Opin Ther Pat. 2020 Aug;30(8):633-641. doi: 10.1080/13543776.2020.1789100. Epub 2020 Jul 20.
Leishmaniasis is a neglected tropical disease caused by protozoa of the genus . Worldwide, approximately 1.5-2 million new cases of leishmaniasis and 20,000-30,000 deaths occurs each year. Effective treatment for all forms of leishmaniasis have numerous adverse effects contributing to poor adherence and/or treatment interruption by the patient. Development of novel therapies, as multitarget drugs, for example, can contribute to accelerate discover safer, more active, and patient-compliant drugs for leishmaniasis treatment.
In this review, authors summarize pharmaceutical agents for treatment of leishmaniasis developed between 2014 and 2019, which includes synthetic and natural drugs for specific treatments, as well as considering new approaches and strategies using drug delivery system.
Universities or public research institutes produced most of the patents related to pharmaceutical agents for treatment of leishmaniasis in this review, and the majority of the inventions disclosed did not conduct clinical trials. In other words, there is still a lot of investment to be done for the identification of new drugs.
利什曼病是一种由原生动物属引起的被忽视的热带病。全世界每年约有 150 万至 200 万例新发病例和 2 万至 3 万人死亡。所有形式的利什曼病的有效治疗都有许多不良反应，导致患者的依从性差和/或治疗中断。开发新的治疗方法，例如多靶点药物，可以加速发现更安全、更有效、更符合患者需求的利什曼病治疗药物。
在这篇综述中，作者总结了 2014 年至 2019 年间开发的用于治疗利什曼病的药物制剂，其中包括针对特定治疗的合成药物和天然药物，以及考虑使用药物传递系统的新方法和策略。
在这篇综述中，与治疗利什曼病的药物制剂相关的专利主要由大学或公共研究机构产生，所披露的大多数发明都没有进行临床试验。换句话说，为了确定新药，仍有大量的投资需要进行。
